Compare · CRMD vs OUST
CRMD vs OUST
Side-by-side comparison of CorMedix Inc. (CRMD) and Ouster Inc. (OUST): market cap, price performance, sector, and recent activity on the wire.
Summary
- CRMD operates in Health Care, while OUST operates in Industrials - the two are in different parts of the market.
- OUST is the larger of the two at $518.2M, about 3.3x CRMD ($155.0M).
- OUST has been more active in the news (14 items in the past 4 weeks vs 5 for CRMD).
- OUST has more recent analyst coverage (18 ratings vs 7 for CRMD).
- Company
- CorMedix Inc.
- Ouster Inc.
- Price
- -
- -
- Market cap
- $155.0M
- $518.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 5
- 14
- Recent ratings
- 7
- 18
CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Ouster Inc.
Ouster, Inc. designs and manufactures digital lidar sensors for industrial automation, smart infrastructure, robotics, and automotive markets. Its product portfolio includes OS0, and ultra-wide view digital lidar; OS1, a mid-range digital lidar; OS2, a long-range digital lidar; and ES2 digital lidar. The company is based in San Francisco, California.
Latest CRMD
- Today's Stocks in the News
- SEC Form 10-Q filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- CorMedix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
- CorMedix Inc. filed SEC Form 8-K: Other Events
- CorMedix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant
- SEC Form S-8 POS filed by CorMedix Inc.
- CorMedix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest OUST
- GUSS Automation, a wholly owned John Deere Subsidiary, Plans to Advance Precision Autonomy in High-Value Crops with Ouster's Next-Generation REV8 Digital Lidar
- Chief Financial Officer Gianella Kenneth P. sold $1,813,278 worth of shares (40,000 units at $45.33) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 261,014 units (SEC Form 4)
- SEC Form 144 filed by Ouster Inc.
- Trossen Robotics and Stereolabs, an Ouster Subsidiary, Partner to Put High-Fidelity Stereo Vision at the Heart of Physical AI Data Collection
- Ouster BlueCity with REV8 Lidar Wins Multimillion-Dollar Utah Traffic Modernization Expansion
- Director Skaggs Stephen A sold $227,702 worth of shares (5,000 units at $45.54) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 61,415 units (SEC Form 4)
- Ouster Announces Upcoming Investor Events
- SEC Form 10-Q filed by Ouster Inc.
- Ouster Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ouster Announces Results for Second Quarter 2026